For patients who need hematopoietic stem cell transplant

Stem cell transplantation is an effective treatment for leukemia and other hematological diseases, aimed at rebuilding a healthy hematopoietic system. Our team conducts all tests related to stem cell transplantation, including DSA detection, cell procurement, and transfusion management. These tests are performed by experienced professionals who prioritize patient safety and ensure the quality of the stem cell products used. At the same time, we work to enhance the success rate and efficiency of the procedures.

Our team received accreditation from AABB, the most authoritative organization of blood medicine and cell therapy, in both 2021 and 2023, demonstrating our contributions to the field of cell therapy have been internationally recognized. We place great emphasis on report accuracy, helping clinicians make precise diagnoses and treatment decisions. Our contributions are reflected in improved patient satisfaction and higher success rates. We demonstrate our expertise in stem cell testing by conducting research, collaborating with clinical departments, and participating in international conferences.

• Detecting Donor-Specific Antibodies (DSA) and using desensitization to accelerate neutrophil (ANC) and platelet (PLT) engraftment, and to improve success rates in mismatched allogeneic transplantation.

• Providing post-thawing tests for stem cell products to help clinicians accurately understand the condition of thawed products.

• Providng HLA matched PLT to ensure transfusion efficiency and reduce waste of medical resources.

• More than 6500 cases of PBSC collection

• More than 4600 cases of HSCT

• More than 40000 HLA SBT samples

• Reports accuracy: 99.987%

• 2020-2022 The actual 1-year survival of first allogenic transplant: 79.9%

CAP proficiency test pass rate: 99.4%

• Patient satisfication reach to 96.22 in 2024

• Doctors satisfication reach to 89.91 in 2024

• Nurses satisfication reach to 84.55 in 2024

• The first medical center in Asia to receive AABB accreditation as a cell therapy facility.

• Has held CAP accreditation since 2000.

• A total of 91 papers related to HSCT and transfusion have been published.

• Enhancing the survival rate of hematopoietic stem cell transplant patients.

• Increasing transfusion safety through precise transfusion practices.